Screener
Crinetics Pharmaceuticals CRNX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $12,879 | $22,611 |
| Accrued clinical trial costs | 10,084 | 7,369 |
| Accrued outside services and professional fees | 5,739 | 4,430 |
| Accrued research and development costs | 5,673 | 4,506 |
| Other accrued expenses | 3,112 | 2,854 |
| Total | $37,487 | $41,770 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's accrued expenses?
- Crinetics Pharmaceuticals (CRNX) reported accrued expenses of $3.11M in Q1 2026.
- What is the long-term trend for Crinetics Pharmaceuticals's accrued expenses?
- Over 4 years (2020 to 2025), Crinetics Pharmaceuticals's accrued expenses has grown at a 36.0% compound annual growth rate (CAGR), from $835K to $2.85M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Crinetics Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude